Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker MAKO Purchase Could Preview Ortho’s Future

This article was originally published in The Gray Sheet

Executive Summary

Market-leading orthopedic firms have mostly come up with incremental product updates in response to the growing tide of more technology-heavy upstarts. That is what makes Stryker’s $1.65 billion acquisition of MAKO Surgical stand out.

You may also be interested in...



People Briefs

Israeli firm Insightec appoints former Mako Surgical co-founder and chair as CEO, ACell taps new president and CEO, and more personnel updates from JenaValve Technology, Zeltiq and Reva Medical.

FDA Clears Stryker's Mako Robot To Treat Total Hip Replacement

Stryker advanced its robotic-assisted surgery opportunity with its 510(k) clearance to use its Mako system for total hip replacement surgeries. The large joint replacement manufacturer's long-term strategy is to make medical robotics that will be adopted by hospitals because their machines are compatible with different Stryker joints.

Stryker Bucks Trend With Strong Recon Sales

Stryker’s second-quarter sales figures paint the U.S. joint reconstruction market in a more positive light than some feared earlier in the month.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel